{
    "2018-04-24": [
        [
            {
                "time": "",
                "original_text": "受累对赌失利去年亏损5.37亿 沃森生物自主疫苗业务今年延续增长",
                "features": {
                    "keywords": [
                        "对赌失利",
                        "亏损",
                        "沃森生物",
                        "自主疫苗",
                        "增长"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "沃森生物: 研发布局进入收获期 新品上市逐渐发力",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "研发",
                        "新品",
                        "收获期",
                        "逐渐发力"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "沃森生物：公司一季度扭亏 买入评级",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "一季度",
                        "扭亏",
                        "买入评级"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "165家公司下修年度业绩预期，业绩变脸痼疾亟待多维施治",
                "features": {
                    "keywords": [
                        "165家公司",
                        "下修",
                        "年度业绩",
                        "业绩变脸",
                        "多维施治"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}